MannKind | MNKD - Current Assets


MannKind reported $245.71M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Adma Biologics USD 528.2M 17.03M Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
MannKind USD 245.71M 5.45M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 771.1M 79.72M Jun/2026
Novo Nordisk DKK 31.89B 145.42B Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Xencor USD 523.21M 40.36M Jun/2026